Jay Darden, a partner in the firm’s Washington office, was featured in The New York Times on August 13, 2010, about a broad federal investigation into whether major drug and device makers have made illegal payments to health professionals and doctors in foreign countries to encourage them to order or prescribe their medications.
Manyforeign countries, forbid doctors from marketing drugs and medical devicesas they can in the United States. If payments to doctors by drug and device makers are not disclosed to the governments, there may be a violation of the Foreign Corrupt Practices Act. Drug companies need to be remindful to their foreign subsidiaries not to make bribes to local officials and doctors, according to the article.
“They should set a tone at the top that makes it clear to a company’s international sales force that these types of payments are unacceptable,” Mr. Darden said.